Seagen Inc.

Seattle Genetics, Inc.

Lori Westendorf

Michael Feldhaus

Django Sussman

Maureen Ryan

Timothy S Lewis

Shyra Gardai

Vivian Trang

Matthew R Levengood

Christopher Carosino

Eric Bradley Meyer

Heather Jean Kostner

Che Leung-Law

Patrick J Burke

Che-Leung Law

William Arthur

May Kung Sutherland

Travis Biechele

Sharsti Sandall

Kristine Gordon

Timothy Lewis

Provided are novel anti-αvβ6 antibodies and antibody-drug conjugates and methods of using such anti-αvβ6 antibodies and antibody-drug conjugates to treat cancer.

Anti-αVβ6 antibodies and antibody-drug conjugates

Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

CD47 antibodies and uses thereof for treating cancer

Provided are novel anti-&#x3b1;v&#x3b2;6 antibodies and antibody-drug conjugates and methods of using such anti-&#x3b1;v&#x3b2;6 antibodies and antibody-drug conjugates to treat cancer.

Anti-AVB6 antibodies and antibody-drug conjugates

The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.

Glypican 3 antibodies and conjugates thereof

The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.

BCMA antibodies and use of same to treat cancer and immunological disorders

Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.

Anti-CD228 antibodies and antibody-drug conjugates

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.

Anti-NTB-A antibodies and related compositions and methods

The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.

CD123 antibodies and conjugates thereof

The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD48 and conjugates thereof.

Growing community of inventors

Snohomish, WA, United States of America

Lori Westendorf